• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

    3/6/25 8:00:00 AM ET
    $ECOR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ECOR alert in real time by email

    ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024, after market close on Wednesday, March 12, 2025.

    Management will host a webcast and conference call at 5:30 PM EDT to discuss the financial results and answer questions.

    Conference Call & Webcast Details

    Date: Wednesday, March 12, 2025

    Time: 5:30 PM EDT

    Registration: Click here to register to receive login credentials and dial-in details.

    About electroCore, Inc.

    electroCore, Inc. is a commercial-stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (nVNS) technology platform. The company focuses on commercializing medical devices for managing and treating specific medical conditions, as well as consumer products utilizing nVNS to enhance general well-being and human performance in the United States and select international markets.

    For more information, visit www.electrocore.com.

    Contact:

    ECOR Investor Relations

    (973) 302-9253

    [email protected]



    Primary Logo

    Get the next $ECOR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ECOR

    DatePrice TargetRatingAnalyst
    1/19/2022$3.00 → $2.75Buy
    HC Wainwright & Co.
    7/27/2021$3.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ECOR
    SEC Filings

    See more
    • SEC Form SCHEDULE 13D filed by electroCore Inc.

      SCHEDULE 13D - electroCore, Inc. (0001560258) (Subject)

      5/14/25 9:02:34 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by electroCore Inc.

      10-Q - electroCore, Inc. (0001560258) (Filer)

      5/7/25 4:30:50 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • electroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - electroCore, Inc. (0001560258) (Filer)

      5/7/25 4:25:21 PM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ECOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on electroCore with a new price target

      HC Wainwright & Co. reiterated coverage of electroCore with a rating of Buy and set a new price target of $2.75 from $3.00 previously

      1/19/22 6:31:24 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Ladenburg Thalmann initiated coverage on electroCore with a new price target

      Ladenburg Thalmann initiated coverage of electroCore with a rating of Buy and set a new price target of $3.00

      7/27/21 7:13:01 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Maxim Group resumed coverage on electroCore with a new price target

      Maxim Group resumed coverage of electroCore with a rating of Buy and set a new price target of $3.00

      3/13/21 8:17:18 AM ET
      $ECOR
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care